<DOC>
	<DOCNO>NCT02448446</DOCNO>
	<brief_summary>This open-label , Phase I/II study intravitreally administer 0.3mg ranibizumab subject diabetic macular edema lipid exudate central subfield .</brief_summary>
	<brief_title>The Effect Intravitreal Ranibizumab Visual Acuity Hard Exudate Resolution Treatment Diabetic Macular Edema With Center Involved Edema Lipid Exudates</brief_title>
	<detailed_description>This open-label , Phase I/II study intravitreally administer 0.3mg ranibizumab subject diabetic macular edema lipid exudate central subfield . Consented , enrolled subject receive multiple open-label intravitreal injection 0.3mg ranibizumab administer every 30 day 12 month per treatment algorithm . The patient randomize 1 2 treatment group . Group 1 : Treatment algorithm base Diabetic Retinopathy Clinical Research ( DRCR ) protocol I 4:2:7 strategy base presence macular edema . Group 2 : Continue treatment macular edema resolve also lipid exudate resolve . Sample size : 30 eye Follow-up Schedule : Every 4 week throughout study .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : Inclusion Criteria Ability provide write informed consent comply study assessment full duration study Age ≥ 18 year Type 1 Type 2 Diabetes mellitus Best correct ETDRS visual acuity ( 20/3220/320 ) letter score 78 24 Diabetic macular edema clinical examination involve center macula assess main cause visual loss Retinal thickness measure spectral domain optical coherence tomography ( OCT ) . Zeiss Cirrus : ≥290μm woman ≥305 μm men central subfield . Heidelberg Spectralis : ≥305μm woman ≥320 μm men central subfield Lipid exudate involve central subfield spectral domain OCT. Exclusion Criteria Subjects meet follow criterion exclude study : Treatment diabetic macular edema within prior 4 month . Panretinal photocoagulation within prior 4 month anticipate need panretinal photocoagulation within next 6 month major ocular surgery within prior 4 month myocardial infarction , cardiac event require hospitalization , cerebrovascular accident , transient ischemic attack , treatment acute congestive heart failure occur within 4 month randomization Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , intrauterine device ( IUD ) , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>